Unrealized Gain (Loss) on Equity Securities
Neurocrine Biosciences Unrealized Gain (Loss) on Equity Securities decreased by 17.3% to $25.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 182.7%, from -$30.60M to $25.30M. Over 3 years (FY 2021 to FY 2024), Unrealized Gain (Loss) on Equity Securities shows a downward trend with a 21.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase signals positive market performance of the company's investment portfolio, while a decrease signals market-driven losses.
Detailed definition
Reflects the change in fair value of equity investments held by the company that have not yet been sold. These fluctuati...
Peer comparison
Common for companies with significant treasury or strategic investment portfolios; varies widely based on market conditions.
wmt_unrealized_gain_loss_equity_securitiesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | -$8.20M | $28.40M | $19.90M | -$7.40M | $11.10M | $7.20M | $2.20M | $37.30M | -$40.10M | $29.00M | $1.60M | -$19.90M | -$16.90M | -$1.90M | -$30.60M | -$6.70M | $30.60M | $25.30M |
| QoQ Change | — | — | +446.3% | -29.9% | -137.2% | +250.0% | -35.1% | -69.4% | >999% | -207.5% | +172.3% | -94.5% | <-999% | +15.1% | +88.8% | <-999% | +78.1% | +556.7% | -17.3% |
| YoY Change | — | — | — | — | — | +235.4% | -74.6% | -88.9% | +604.1% | -461.3% | +302.8% | -27.3% | -153.4% | +57.9% | -106.6% | <-999% | +66.3% | +281.1% | +182.7% |
Business Segments
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 |
|---|---|---|---|---|
| Reportable Segment | -$30.60M | -$6.70M | $30.60M | $25.30M |
| Total | -$30.60M | -$6.70M | $30.60M | $25.30M |
Unrealized Gain (Loss) on Equity Securities at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's unrealized gain (loss) on equity securities?
- Neurocrine Biosciences (NBIX) reported unrealized gain (loss) on equity securities of $25.30M in Q1 2026.
- How has Neurocrine Biosciences's unrealized gain (loss) on equity securities changed year-over-year?
- Neurocrine Biosciences's unrealized gain (loss) on equity securities increased by 182.7% year-over-year, from -$30.60M to $25.30M.
- What is the long-term trend for Neurocrine Biosciences's unrealized gain (loss) on equity securities?
- Over 3 years (2021 to 2024), Neurocrine Biosciences's unrealized gain (loss) on equity securities has grown at a 21.1% compound annual growth rate (CAGR), from $20.90M to -$37.10M.
- What does unrealized gain (loss) on equity securities mean?
- The change in value of stock investments that the company still owns.